Loading...

Celularity Inc.

CELUW•NASDAQ
Healthcare
Biotechnology
$0.06
$0.006(11.20%)

Celularity Inc. (CELUW) Stock Overview

Explore Celularity Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 59.8/100

Key Financials

Market Cap1.2M
P/E Ratio-0.65
EPS (TTM)$-0.87
ROE-3.35%
Fundamental Analysis

AI Price Forecasts

1 Week$0.05
1 Month$0.04
3 Months$0.12
1 Year Target$0.02

CELUW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Celularity Inc. (CELUW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 53.15, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.02.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.65 and a market capitalization of 1.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

53.15RSI (14)
0.00MACD
66.29ADX
Stats data is not available for CELUWStats details for CELUW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CELUWAnalyst Recommendations details for CELUW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

CEO

Robert Joseph Hariri

Employees

120

Headquarters

170 Park Avenue, Florham Park, NJ

Founded

2021

Frequently Asked Questions

;